GlucoTrack Ownership
| GCTK Stock | USD 0.24 0.01 4.00% |
Shares in Circulation | First Issued 2011-03-31 | Previous Quarter 5.5 M | Current Value 5.5 M | Avarage Shares Outstanding 6.2 M | Quarterly Volatility 7.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
GlucoTrack |
GlucoTrack Stock Ownership Analysis
About 35.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.91. GlucoTrack had not issued any dividends in recent years. The entity had 1:5 split on the 20th of May 2024. GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel. Glucotrack operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. To learn more about GlucoTrack call the company at 201 842 7715 or check out https://glucotrack.com.Besides selling stocks to institutional investors, GlucoTrack also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different GlucoTrack's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align GlucoTrack's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
GlucoTrack Quarterly Liabilities And Stockholders Equity |
|
About 35.0% of GlucoTrack are currently held by insiders. Unlike GlucoTrack's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against GlucoTrack's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of GlucoTrack's insider trades
GlucoTrack Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as GlucoTrack is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GlucoTrack backward and forwards among themselves. GlucoTrack's institutional investor refers to the entity that pools money to purchase GlucoTrack's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 27.2 K | Alerus Financial Na | 2024-09-30 | 13.9 K | Cetera Investment Advisers | 2024-06-30 | 10 K | Ubs Group Ag | 2024-06-30 | 6.1 K | Renaissance Technologies Corp | 2024-06-30 | 0.0 | Susquehanna International Group, Llp | 2024-06-30 | 0.0 | Sabby Management Llc | 2024-06-30 | 0.0 | Accurate Wealth Management, Llc | 2024-06-30 | 0.0 | Virtue Capital Management, Llc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
GlucoTrack Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GlucoTrack insiders, such as employees or executives, is commonly permitted as long as it does not rely on GlucoTrack's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GlucoTrack insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Darivoff Philip over a month ago Discretionary transaction by Darivoff Philip of tradable shares of GlucoTrack at 5.8 subject to Rule 16b-3 | ||
Paul Goode over three months ago Acquisition by Paul Goode of 42000 shares of GlucoTrack at 4.95 subject to Rule 16b-3 | ||
Darivoff Philip over six months ago Discretionary transaction by Darivoff Philip of tradable shares of GlucoTrack at 5.8 subject to Rule 16b-3 | ||
Darivoff Philip over six months ago Discretionary transaction by Darivoff Philip of tradable shares of GlucoTrack subject to Rule 16b-3 | ||
Seff Leslie over six months ago Acquisition by Seff Leslie of 22727 shares of GlucoTrack at 1.98 subject to Rule 16b-3 |
GlucoTrack Outstanding Bonds
GlucoTrack issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. GlucoTrack uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most GlucoTrack bonds can be classified according to their maturity, which is the date when GlucoTrack has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US45824TBC80 Corp BondUS45824TBC80 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| IFCCN 5459 22 SEP 32 Corp BondUS45823TAL08 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. If investors know GlucoTrack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlucoTrack listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.91) | Return On Assets (1.57) | Return On Equity (5.41) |
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlucoTrack's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.